title: Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
authors.forename: M K
authors.initials: MK
authors.lastname: de Vries
authors.forename: G J
authors.initials: GJ
authors.lastname: Wolbink
authors.forename: S O
authors.initials: SO
authors.lastname: Stapel
authors.forename: E R
authors.initials: ER
authors.lastname: de Groot
authors.forename: B A C
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: L A
authors.initials: LA
authors.lastname: Aarden
authors.forename: I E
authors.initials: IE
authors.lastname: van der Horst-Bruinsma
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood / Q000276:immunology / Q000627:therapeutic use*; D000917:Antibody Formation; D018501:Antirheumatic Agents / Q000097:blood / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000276:immunology; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab